Cite
HARVARD Citation
Hammerman, A. et al. (2022). Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6. Postgraduate medicine. 134 (7), pp. 654-658. [Online].